Clinical Trial

CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results

GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC)…

26 minutes ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 15,…

18 hours ago

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant…

18 hours ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc”…

18 hours ago

Metabolon Appoints Celia Reyes as Vice President of Human Resources

Celia Reyes will lead Metabolon's global people strategy as the company continues to scale in the evolving multiomics marketplaceMORRISVILLE, N.C.,…

2 days ago

Metabolon Appoints Celia Reyes as Vice President of Human Resources

Celia Reyes will lead Metabolon's global people strategy as the company continues to scale in the evolving multiomics marketplaceMORRISVILLE, N.C.,…

2 days ago

Aspire Biopharma Announces Reverse Stock Split

ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a…

2 days ago

Zomedica Announces “Fourth Friday at Four” Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth

January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January…

2 days ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 days ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx,…

2 days ago